Oncotype Dx was initially analyzed in clinical trials in 2004 and shown to be capable of quantifying the probability of distant recurrence and likelihood of response to chemotherapy in early hormone receptor-positive BC [4, 10]. The gene discussed is NR4A1; the disease is breast cancer.